Domo signs strategic collaboration agreement with AWS for AI solutions
BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment with a market capitalization of $2.6 billion, today announced significant executive team changes aimed at bolstering its late-stage clinical development efforts. The company, which has demonstrated strong financial health with a current ratio of 26.35, maintains a solid balance sheet according to InvestingPro data. The company has appointed Robert Blaustein, M.D., Ph.D., as Chief Development Officer (CDO) and promoted Behrad Derakhshan, Ph.D., to Chief Operating Officer (COO).
Dr. Blaustein, with extensive experience in cardiovascular drug development, joins Edgewise from Merck (NSE:PROR), where he led late phase development efforts in atherosclerosis and heart failure, including the Phase 3 VICTORIA heart failure trial. He will now lead the development of EDG-7500, a novel cardiac sarcomere modulator in Phase 2 development, along with the company's cardiovascular and cardiometabolic pipeline.
Dr. Derakhshan, previously serving as Chief Business Officer since 2020, played a pivotal role in Edgewise's successful initial public offering and subsequent funding rounds. His promotion to COO is a strategic move to prepare the company for upcoming milestones in its muscular dystrophy and cardiovascular programs as it transitions toward commercial readiness. The company's stock has shown remarkable strength, delivering a 76% return over the past year, though InvestingPro analysis suggests the stock is currently trading near its Fair Value.
The company also acknowledged the departure of the current CDO, Dr. Semigran, who will remain as a clinical advisor to ensure a smooth transition. Under Dr. Semigran's leadership, the company advanced EDG-7500 in the clinic, with positive topline data from its Phase 1 trial and the ongoing Phase 2 CIRRUS-HCM trial in patients with hypertrophic cardiomyopathy.
These leadership changes are effective immediately and reflect Edgewise's commitment to advancing its pipeline of therapies for serious muscle diseases, including its first-in-class fast skeletal myosin inhibitor, Sevasemten, in late-stage clinical trials for Becker and Duchenne muscular dystrophies.
Edgewise Therapeutics continues to focus on developing novel treatments for muscular dystrophies and serious cardiac conditions, leveraging its expertise in muscle physiology to create a new generation of therapies. The company maintains its dedication to changing the lives of patients and families affected by serious muscle diseases. With its next earnings report scheduled for February 20, 2025, investors can access comprehensive analysis and additional insights through InvestingPro's detailed research reports, which cover over 1,400 US stocks including EWTX.
This article is based on a press release statement from Edgewise Therapeutics.
In other recent news, Edgewise Therapeutics has been the focus of several analyst notes and has reported significant progress in its clinical trials. Stifel initiated coverage of Edgewise with a Hold rating and a $30 target, highlighting the potential of its clinical-stage assets, EDG-7500 and sevasemten, while recognizing the risks involved in their development. Truist Securities reiterated a Buy rating on the company following positive results from its Phase 2 CANYON trial testing sevasemten. The trial achieved its primary endpoint, demonstrating stabilization of motor function in patients with Becker muscular dystrophy.
Piper Sandler identified Edgewise as one of several companies with key Phase 2b readouts expected in 2025, indicating a significant period ahead for the company. In response to an FDA warning issued to a researcher not associated with Edgewise, the company confirmed its compliance with FDA requirements, ensuring the integrity of its ongoing clinical trials. These recent developments underscore the active role Edgewise Therapeutics is playing in the biotechnology sector, particularly in the development of therapies for serious, rare muscle disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.